07:39 AM EDT, 09/03/2024 (MT Newswires) -- Merck ( MRK ) said Tuesday the European Commission approved the drug combination of Keytruda and Padcev for treatment of urothelial carcinoma, the most common type of bladder cancer, in adults.

The indication is for Merck's ( MRK ) proprietary treatment Keytruda combined with Padcev, jointly developed by Astellas Pharma and Seattle Genetics, in unresectable or metastatic bladder cancer.

Price: 118.40, Change: -0.05, Percent Change: -0.04